Sandra Calvin sold $139k of TVTX
SVP, CHIEF ACCOUNTING OFFICER at Travere Therapeutics, Inc.. 4,333 shares at an average of $32.12, traded Feb 3, 2026, filed Feb 3, 2026.
Score components
- +15RoleOfficer
- +11Trade size$139k at market
- 0Share of holdings soldSold 8.1% of holdings
- +15Cluster7 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -16.8%, 3m +36.4%, 6m +70.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001882909-26-000001, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 31, 2026 | AGrant or award Common Stock | +15,180 | $0.00 | $0 | 53,413 | Feb 3, 2026 |
| Feb 3, 2026 | SOpen-market sale Common Stock | -4,333 | $32.12 | $139k | 49,080 | Feb 3, 2026 |
| Jan 31, 2026 | AGrant or award Employee stock option (right to buy)derivative | +20,160 | $0.00 | $0 | 20,160 | Feb 3, 2026 |
Related signals
Other insiders at Travere Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Travere Therapeutics, Inc. | Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER | $335k 5,375 shares | -11% | |
| 37Weak | Travere Therapeutics, Inc. | Christopher R. Cline CHIEF FINANCIAL OFFICER | $3.1M 50,508 shares | -37% | |
| 50Moderate | Travere Therapeutics, Inc. | Eric M Dube CHIEF EXECUTIVE OFFICER | $25M 400,000 shares | -76% | |
| 40Moderate | Travere Therapeutics, Inc. | Peter Heerma EVP, CHIEF COMMERCIAL OFFICER | $18M 283,189 shares | -129% | |
| 30Weak | Travere Therapeutics, Inc. | Jula Inrig EVP, Head of R&D & CMO | $2.8M 44,674 shares | -31% | |
| 30Weak | Travere Therapeutics, Inc. | Elizabeth E Reed Chief Legal Officer and GC | $2.3M 37,500 shares | -26% | |
| 40Moderate | Travere Therapeutics, Inc. | William E. Rote Chief Research Officer | $13M 209,048 shares | -108% | |
| 25Weak | Travere Therapeutics, Inc. | Jeffrey A Meckler director | $1.3M 20,000 shares | -18% | |
| 43Moderate | Travere Therapeutics, Inc. | Christopher R. Cline CHIEF FINANCIAL OFFICER | $43k 642 shares | -1% | |
| 5Weak | Travere Therapeutics, Inc. | Gary A Lyons director | $633k 10,000 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.